C. Van Sant
Astellas Pharma (United States) · 9 works · 644 citations · h-index 4
Top works
- Antibody to hepatitis C virus second envelope (HCV‐E2) glycoprotein: A new marker of HCV infection closely associated with viremia
- Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3
- The null mutant of the U(L)31 gene of herpes simplex virus 1: construction and phenotype in infected cells
- A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
- Baton-Crc: a Phase 2 Randomized Trial Comparing Tivozanib (Tivo) + Mfolfox6 with Bevacizumab (Bev) + Mfolfox6 in Stage Iv Metastatic Colorectal Cancer (Mcrc)
- O-007 Neuropilin 1 (NRP1) may be prognostic and identify a subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib + mFOLFOX6 compared to Bevacizumab + mFOLFOX6
- 225 POSTER Endothelin signaling in osteoblastic metastases: molecular mechanisms and biomarkers
- 311 POSTER Early discovery of genomic correlates of drug response by high-resolution gene copy number profiling
- 334 Gene Expression Analysis of Human Sarcoma Tissues to Explore Clinical Outcomes of mTOR Inhibition with Ridaforolimus: Correlative Science From the Phase III SUCCEED Trial Testing Maintenance Therapy for Metastatic Disease